CRSP News and Press, CRISPR Therapeutics AG From 02/09/24

2024-02-09 06:25:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare stocks are one of the best sectors to capture long-term innovation and sector strength. After all, healthcare needs are perennial, especially as the global population lives longe...

2024-02-08 21:37:41 ET Summary Intellia is adopting a distinct strategy by focusing on in-vivo gene editing, potentially redefining industry standards and expectations. Interim results from Intellia's in-vivo gene-editing program for ATTR amyloidosis show promising safety and effi...

2024-02-08 02:59:00 ET Many investors believe in the January Effect, or the idea that the stock market tends to go on a run during the first month of the year. Whether or not this effect is real, investing in a company based on it is not a good idea. Investors would be better off focusing o...

2024-02-02 17:11:18 ET More on CRISPR Therapeutics, Takeda Pharmaceutical, etc. Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off ...

2024-02-01 13:20:32 ET Summary Crispr Therapeutics recently received FDA approval for gene editing therapy, Casgevy for treating Sickle Cell Disease and Beta-Thalassemia. In this article I'll look at Casgevy's market potential and its commercialisation challenges. The cost of ...

2024-01-30 05:02:00 ET CRISPR Therapeutics (NASDAQ: CRSP) soared 54% last year as growth stocks rallied and the company itself moved toward an important milestone: the approval of its very first product. The gene editing specialist won the world's first nod for a CRISPR-based gene e...

2024-01-25 10:57:50 ET Summary More than one year into the Launch of Zynteglo and Skysona, BLUE's sales remain underwhelming. The company launched a third gene therapy, Lyfgenia, but faces similar commercialization challenges. High treatment costs, limited patient base, outsou...

2024-01-25 08:00:00 ET Summary Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected. Competitive stories in gene editin...

2024-01-23 09:30:00 ET With CRISPR Therapeutics (NASDAQ: CRSP) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly. Between the fruits of its ongoing commercialization process an...

2024-01-22 13:52:27 ET Summary The FDA approved Casgevy, a CRISPR/Cas9 gene-edited therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older last week. The market has reacted negatively to the approval, causing a drop in stock prices for Vertex and C...